LLSATNCT04167358
Linerixibat Long-term Safety, and Tolerability Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 39 versions: 38 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 19 words Show 4 more changesShow less
- Trial completed
- Start date: Jul 14, 2020 to Jul 8, 2020
- Secondary endpoints: details revised at 8 of 9 entries
- Site details revised at 18 of 94 sites
- Minor Trial sites expanded: 89 → 94 locationsv38
- Minor Enrollment target: 245 to 242
- Study sites: 95 to 89
- Primary and study completion dates: Aug 31, 2027 to Sep 30, 2026
- Minor Site details revised at 3 of 95 sitesv36
- Minor Enrollment target: estimated 251 to confirmed 245v35
Show 32 earlier versionsHide 32 earlier versions
- Notable Primary and study completion dates: Feb 2, 2027 to Aug 31, 2027
- Trial status: Recruiting to Active, Not Recruiting
- Study sites: 94 to 95
- Minor Site details revised at 9 of 94 sitesv33
- Minor Enrollment target: 305 to 251
- Study sites: 111 to 94
- Notable Primary and study completion dates: Dec 23, 2025 to Feb 2, 2027
- Study sites: 52 to 111
- Minor Study sites: 48 to 52v30
- Minor Study sites: 42 to 48v29
- Minor Study sites: 30 to 42v28
- Notable Eligibility criteria expanded, about 8 words
- Secondary endpoints revised (9)
- Minor Study sites: 28 to 30v26
- Minor Study sites: 27 to 28v25
- Notable Primary and study completion dates: Dec 9, 2024 to Dec 23, 2025
- Study sites: 26 to 27
Notable Enrollment target: 75 to 305v23 Show 4 more changesShow less
- Eligibility criteria shortened, about 265 words
- Study sites: 24 to 26
- Secondary endpoints: 8 to 9
- Study title revised
- Minor Study sites: 22 to 24v22
- Minor Study sites: 21 to 22v21
- Minor Study sites: 19 to 21v20
- Minor Study sites: 18 to 19v19
- Minor Study sites: 17 to 18v18
- Minor Study sites: 12 to 17
- Start date: Jul 8, 2020 to Jul 14, 2020
- Minor Study sites: 11 to 12v16
- Minor Study sites: 10 to 11v15
- Minor Study sites: 6 to 10v14
- Minor Study sites: 5 to 6v13
- Minor Study sites: 4 to 5v12
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 4
- Primary and study completion dates: Dec 24, 2024 to Dec 9, 2024
- Start date changed from estimate of Jul 6, 2020 to Jul 8, 2020
- Notable Start date: Jun 2, 2020 to Jul 6, 2020
- Study sites: 0 to 1
- Primary and study completion dates: Nov 20, 2024 to Dec 24, 2024
- Minor Primary and study completion dates: Oct 22, 2024 to Nov 20, 2024
- Start date: May 4, 2020 to Jun 2, 2020
- Notable Start date: Apr 2, 2020 to May 4, 2020
- Primary and study completion dates: Sep 20, 2024 to Oct 22, 2024
- Minor Primary and study completion dates: Sep 9, 2024 to Sep 20, 2024
- Start date: Mar 20, 2020 to Apr 2, 2020
- Minor Primary and study completion dates: Aug 22, 2024 to Sep 9, 2024
- Start date: Mar 4, 2020 to Mar 20, 2020
- Notable Eligibility criteria expanded, about 7 words
- Enrollment target: 80 to 75
- Secondary endpoints: 7 to 8
- Notable Start date: Jan 20, 2020 to Mar 4, 2020
- Primary and study completion dates: Jul 1, 2024 to Aug 22, 2024
- Minor Start date: Jan 10, 2020 to Jan 20, 2020v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with non-serious adverse events (AEs) and Serious AEs (SAEs)
Timeframe: Up to 66 months
Number of participants with Severe AEs
Timeframe: Up to 66 months
Secondary (9)
Change in domain scores of the PBC-40 over time
Change in health-related quality of life (QoL) by the Euro Quality-5 dimension-3 level (EQ-5D-3L) scores over time (Group 1 only)
Change in self-rated health by EQ VAS scores over time (Group 1 only)
Change in the Beck Depression Inventory (BDI-II) scores over time
Number of participants with clinically significant changes in hematology, biochemistry (including lipid and liver parameters), and coagulation parameters
Show 4 moreShow less
Percentage of responders at Week 24 and Week 52 of continuous treatment (Group 2 only)
Percentage of participants with maintenance of efficacy at Week 52 of continuous treatment in those that were responders at Week 24 of continuous treatment (Group 2 only)
Change from Baseline Monthly Sleep Score (MSS) (Group 2 only)
Change from Baseline in Monthly Fatigue Score (MFS)(Group 2 only)
Arms and interventions
Participants receiving linerixibatExperimental
Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER \[Group 1\]) and Phase 3 study (212620 GLISTEN \[Group 2\]), will receive linerixibat.
Drugs: Linerixibat
Sites
94 sites in 17 countries
Japan 19, United States 11, China 9, United Kingdom 9, Italy 8, Argentina 6, Poland 5, Spain 5, Brazil 4, Israel 4, Mexico 3, Russia 3, Canada 2, Czechia 2, Germany 2, Bulgaria 1, France 1